Fillers in the United States
Drs Heidi Waldorf and Doris Day discuss the dermal filler market in the US: what is currently available, what we are likely to see in the next 5 years, and the properties of a hypothetically ‘ideal’ filler.
Read MoreDrs Heidi Waldorf and Doris Day discuss the dermal filler market in the US: what is currently available, what we are likely to see in the next 5 years, and the properties of a hypothetically ‘ideal’ filler.
Read MoreWendy Lewis talks to Philippe Schaison, Corporate Vice President & President, U.S. Medical for Allergan, Inc., on the state of aesthetics in light of the pending battle over BOTOX®.
Read MoreWith an ever increasing number of dermal fillers and neurotoxins on the market, Wendy Lewis provides an insight into their evolving role in aesthetic medicine
Read MoreIn the post-PIP era, the medical aesthetics industry can expect to be dogged by issues of trust and quality. Rosalind Hill speaks to Douglas Ingram about how Allergan plans to address these questions head-on
Read More